Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate

Protein Expression and Purification

Volumn 110, Issue , 2015, Pages 122-129

  Ben David, Alon ^a   Torgeman, Amram ^a   Barnea, Ada ^a   Zichel, Ran ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Botulinum vaccine; His tag protein purification; Recombinant protein expression

Indexed keywords

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS;

BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBOXYLYASE; HIS-HIS-HIS-HIS-HIS-HIS; HISTIDINE; HYBRID PROTEIN; OLIGOPEPTIDE; PROTEIN BINDING; UDPGLUCURONATE DECARBOXYLASE;

ANIMAL; BIOSYNTHESIS; BOTULISM; CHEMICAL STRUCTURE; CHEMISTRY; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MOLECULAR CLONING; MORTALITY; MOUSE; PLASMID; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; SURVIVAL; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; BOTULINUM TOXINS, TYPE A; BOTULISM; CARBOXY-LYASES; CLONING, MOLECULAR; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; GENE EXPRESSION; HISTIDINE; MICE; MODELS, MOLECULAR; OLIGOPEPTIDES; PLASMIDS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINATION;

EID: 84924336447     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2015.02.008     Document Type: Article

References (40)

1. R.G. Darling, C.L. Catlett, K.D. Huebner, and D.G. Jarrett Threats in bioterrorism I: CDC category a agents Emerg. Med. Clin. North Am. 20 2002 273 309
2. L.A. Smith, and J.M. Rusnak Botulinum neurotoxin vaccines: past, present, and future Crit. Rev. Immunol. 27 2007 303 318
3. J.M. Rusnak, and L.A. Smith Botulinum neurotoxin vaccines: past history and recent developments Hum. Vaccin. 5 2009 794 805
4. M. Montal Botulinum neurotoxin a marvel of protein design Annu. Rev. Biochem. 79 2010 591 617
5. L.A. Smith Botulism and vaccines for its prevention Vaccine 27 2009 D33 D39
6. M.A. Clayton, J.M. Clayton, D.R. Brown, and J.L. Middlebrook Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli Infect. Immun. 63 1995 2738 2742
7. M.R. Baldwin, W.H. Tepp, A. Przedpelski, C.L. Pier, M. Bradshaw, E.A. Johnson, and J.T. Barbieri Subunit vaccine against the seven serotypes of botulism Infect. Immun. 76 2008 1314 1318
8. J.D. Shearer, M.L. Vassar, W. Swiderski, K. Metcalfe, N. Niemuth, and I. Henderson Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B) Vaccine 28 2010 7313 7318
9. H.F. LaPenotiere, M.A. Clayton, and J.L. Middlebrook Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen Toxicon 33 1995 1383 1386
10. J. Boles, M. West, V. Montgomery, R. Tammariello, M.L.M. Pitt, P. Gibbs, L. Smith, and R.D. LeClaire Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey Toxicon 47 2006 877 884
11. M.P. Byrne, T.J. Smith, V.A. Montgomery, and L.A. Smith Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate Infect. Immun. 66 1998 4817 4822
12. M.P. Byrne, R.W. Titball, J. Holley, and L.A. Smith Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris Protein Expr. Purif. 18 2000 327 337
13. M.P. Dux, R. Barent, J. Sinha, M. Gouthro, T. Swanson, A. Barthuli, M. Inan, J.T. Ross, L.A. Smith, T.J. Smith, R. Webb, B. Loveless, I. Henderson, and M.M. Meagher Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115 Protein Expr. Purif. 45 2006 359 367
14. M.P. Dux, J. Huang, R. Barent, M. Inan, S.T. Swanson, J. Sinha, J.T. Ross, L.A. Smith, T.J. Smith, I. Henderson, and M.M. Meagher Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(Hc)] expressed in Pichia pastoris Protein Expr. Purif. 75 2011 177 185
15. K.J. Potter, W. Zhang, L.A. Smith, and M.M. Meagher Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris Protein Expr. Purif. 19 2000 393 402
16. M.R. Baldwin, W.H. Tepp, C.L. Pier, M. Bradshaw, M. Ho, B.A. Wilson, R.B. Fritz, E.A. Johnson, and J.T. Barbieri Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E Infect. Immun. 73 2005 6998 7005
17. Y.Z. Yu, S.M. Zhang, Y. Ma, H.Q. Zhu, W.B. Wang, Y. Du, X.W. Zhou, R.L. Wang, S. Wang, W.Y. Yu, P.T. Huang, and Z.W. Sun Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F Clin. Immunol. 137 2010 271 280
18. R. Chen, J. Shi, K. Cai, W. Tu, X. Hou, H. Liu, L. Xiao, Q. Wang, Y. Tang, and H. Wang Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain Protein Expr. Purif. 71 2010 79 84
19. Y.Z. Yu, Z.W. Sun, S. Wang, and W.Y. Yu High-level expression of the Hc domain of clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen Chin. J. Biotechnol. 23 2007 812 817
20. A. Ben David, E. Diamant, A. Barnea, O. Rosen, A. Torgeman, and R. Zichel The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo Clin. Vacc. Immun. 20 2013 1266 1273
21. D.M. Held, A.C. Shurtleff, S. Fields, C. Green, J. Fong, R.G.A. Jones, D. Sesardic, R. Buelow, and R.L. Burke Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B Clin. Vacc. Immun. 17 2010 930 936
22. Y.L. Gao, S. Gao, L. Kang, C. Nie, and J.L. Wang Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen Hum. Vaccin. 6 2010 462 466
23. E. Diamant, B.E. Lachmi, A. Keren, A. Barnea, H. Marcus, S. Cohen, A. Ben David, and R. Zichel Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations PLoS One 9 2014 e87089
24. R. Zichel, A. Mimran, A. Keren, A. Barnea, I. Steinberger-Levy, D. Marcus, A. Turgeman, and S. Reuveny Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system Clin. Vacc. Immun. 17 2010 784 792
25. S.M. Whelan, M.J. Elmore, N.J. Bodsworth, J.K. Brehm, T. Atkinson, and N.P. Minton Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence Appl. Environ. Microbiol. 58 1992 2345 2354
26. D.J. Korz, U. Rinas, K. Hellmuth, E.A. Sanders, and W.D. Deckwer Simple fed-batch technique for high cell density cultivation of Escherichia coli J. Biotechnol. 39 1995 59 65
27. E. Gasteiger, A. Gattiker, C. Hoogland, L. Ivani, R.D. Appel, and A. Bairoch ExPASy: the proteomics server for in-depth protein knowledge and analysis Nucleic Acids Res. 31 2003 3781 3788
28. European Pharmacopoeia, Botulinum antitoxin, 2011.
29. Y. Fundoiano-Hershcovitz, L. Rabinovitch, Y. Langut, V. Reiland, G. Shoham, and Y. Shoham Identification of the catalytic residues in the double-zinc aminopeptidase from Streptomyces griseus FEBS Lett. 571 2004 192 196
30. S. Picaud, M.E. Olsson, and P.E. Brodelius Improved conditions for production of recombinant plant sequitepene synthase in Escherichia coli Protein Expr. Purif. 51 2007 71 79
31. N. Oganeysyan, I. Ankoudinova, S.H. Kim, and R. Kim Effect of osmotic stress and heat shock in recombinant protein overexpression and crystallization Protein Expr. Purif. 52 2007 280 285
32. C.F. Ockenhouse, E. Angov, K.E. Kester, C. Diggs, L. Siosson, and J.F. Cummings Phase I safety and immunogenecity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine Vaccine 24 2006 3009 3017
33. M.A. Thera, O.K. Doumbo, D. Coulibaly, D.A. Diallo, and A.K. Kone Safety and immunogenecity of an AMA-1 malaria vaccine in malian adults: results of a phase 1 randomized control trial PLoS One 3 2008 e1465
34. V.M. Bolanos-Garcia, and O.R. Davies Structural analysis and classification of native proteins from E. coli commonly co-purified by immobilised metal affinity chromatography Biochim. Biophys. Acta 1760 2006 1304 1313
35. G.J. Williams, S.D. Breazeale, C.R.H. Raetz, and J.H. Naismith Structure and function of both domains of ArnA, a dual function decarboxylase and a formyltransferase, involved in 4-amino-4-deoxy-l-arabinose biosynthesis J. Biol. Chem. 280 2005 23000 23008
36. K.R. Andersen, N.C. Leska, and T.U. Schwartz Optimized E. coli expression strain LOBSTR eliminates common contaminants from his-tag purification Proteins 81 2013 1857 1861
37. P.Z. Gatzeva-Topalova, A.P. May, and M.C. Sousa Structure and mechanism of ArnA: conformational change implies ordered dehydrogenase mechanism for polymyxin resistance Structure 13 2005 929 942
38. C. Robichon, J. Luo, T.B. Causey, J.S. Benner, and J.C. Samuelson Engineering Escherichia coli BL21(DE3) derivatives strains to minimize E. coli protein contamination after purification by immobilized metal affinity chromatography Appl. Environ. Microbiol. 77 2011 4634 4646
39. K.J. Potter, M.A. Bevins, E.V. Vassilieva, V.R. Chiruvolu, T. Smith, L.A. Smith, and M.M. Meagher Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris Protein Expr. Purif. 13 1998 357 365
40. M. Dong, D.A. Richard, M.C. Goodnough, W.H. Tepp, E.A. Johnson, and E.R. Chapman Synaptotagmins I and II mediate entry of botulinum neurotoxins B into cells J. Cell Biol. 162 2003 1293 1303